Twenty five years after the first AIDS cases were reported in the U.S., and 19 years after the first AIDS drug was approved, patients finally have their first single-pill, once-a-day treatment against HIV thanks to Bristol-Myers Squibb and Gilead Sciences. Combining three potent anti-HIV drugs — efavirenz, emtricitabine and tenofovir — Atripla is a welcome respite for the hundreds of thousands of HIV-positive patients who have become accustomed to taking dozens of pills and injections a day.